Most Read Articles
6 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 4 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 5 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 4 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).

Rituximab a potential treatment for bullous pemphigoid

01 Jul 2019
A woman who developed severe allergic reactions to anti-depressants nearly died from Steven Johnson Syndrome

Rituximab is a potential immunosuppressive treatment for bullous pemphigoid (BP), yielding high rates of remission, good steroid-sparing activity and an acceptable safety profile, reports a recent study.

Researchers retrospectively reviewed the charts of 20 BP patients (median age at treatment, 71.2 years; 50 percent female) who had received at least one dose of rituximab. Study outcomes included clinical status, BP disease activity index (BPDAI) score and adverse events related to treatment. All patients were given topical corticosteroids to use as needed.

The 20 participants contributed to 206 visits. Seventeen patients received one rituximab course, two received two courses and one received three courses. Patients received their first rituximab dose at an average of 231 days after their first visit, and participants were followed for a mean of 508 days after rituximab treatment.

Kaplan-Meier curves showed that the median time to remission and relapse after rituximab treatment was 196 and 508 days, respectively. Majority (75 percent; n=15) of patients showed durable remission after an average of 169 days after rituximab therapy. Of these, one did not require any adjuvant medication and three were maintained on minimal medication; eight achieved partial response.

Most (60 percent; n=9) of the patients who achieved durable remission no longer required prednisone, whereas those who were still on the medication took an average dose of 7.7 mg.

There were no deaths during the study period; 23 adverse events were reported during pre-rituximab phase and 23 during the post-rituximab phase. However, normalizing to rates per person-year, the incidence rate for adverse events dropped from 1.836 before rituximab to 0.827 after.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Girls with eosinophilic oesophagitis (EoE) who show initial response to directed therapy will tend to continue to respond well to treatment, a recent study has shown.
Pearl Toh, 4 days ago
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Elvira Manzano, 5 days ago
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Tristan Manalac, 4 days ago
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).